uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress
July 02 2021 - 9:00AM
uniQure Announces Presentations at Upcoming International Society
on Thrombosis and Haemostasis (ISTH) Virtual Congress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that eight data presentations, of which
three are oral presentations, will be delivered at the
International Society on Thrombosis and Haemostasis (ISTH) Virtual
Congress being held July 17-21, 2021.
Specific details on uniQure’s presentations at
ISTH include:
- Title: Five Year
Data Confirms Stable FIX Expression and Sustained Reductions in
Bleeding and Factor IX Use Following AMT-060 Gene Therapy in Adults
with Severe or Moderate-Severe Hemophilia B (Abstract OC
26.3)Oral Session Title: Hemostatic Agents and
Hemostatic EfficacyDate and Time: Monday, July 19,
11:00 – 12:00 p.m. EDT
- Title: Clinical Outcomes in Adults with
Hemophilia B With and Without Pre-existing Neutralizing Antibodies
to AAV5: 6 Month Data from the Phase 3 Etranacogene Dezaparvovec
HOPE-B Gene Therapy Trial (Abstract OC 67.3)Oral Session
Title: Safety and Efficacy in Gene Therapy for
HemophiliaDate and Time: Wednesday, July 21, 10:00
– 11:00 a.m. EDT
- Title: Liver Safety Case Report from the Phase
3 HOPE-B Gene Therapy Trial in Adults with Hemophilia B (Abstract
OC 67.4)Oral Session Title: Safety and Efficacy in
Gene Therapy for HemophiliaDate and Time:
Wednesday, July 21, 10:00 – 11:00 a.m. EDT
- Title:
Etranacogene dezaparvovec (AAV5-Padua hFIX variant, AMT-061), an
Enhanced Vector for Gene Transfer in Adults with Severe or
Moderate-Severe Hemophilia B: 2.5 Year data from a Phase 2b Trial
(Live Poster, Abstract LPB0020)Poster Session
Title: Oligonucleotide TherapeuticsLive ePoster
Date and Time: Sunday, July 18, 3:00 – 4:00 p.m. EDT
- Title: 52 Week
Efficacy and Safety of Etranacogene Dezaparvovec in Adults with
Severe or Moderate-Severe Hemophilia B: Data from the Phase 3
HOPE-B Gene Therapy Trial (Abstract PB0653)Date and
Time: All ePosters will be made available on Saturday,
July 17
- Title: Management
of Infusion Reactions: Lessons from the Phase 3 HOPE-B Gene Therapy
Trial of Etranacogene Dezaparvovec in Adults with Hemophilia B
(Abstract PB0659)Date and Time: All ePosters will
be made available on Saturday, July 17
- Title: Real-world
Outcomes in People with Severe Hemophilia B Receiving FIX
Prophylaxis across Europe: A CHESS II Analysis (Abstract
PB0463)Date and Time: All ePosters will be made
available on Saturday, July 17
- Title: Preferences
of People with Hemophilia A and B for Treatments Including Gene
Therapies in the US: A Discrete Choice Experiment (Abstract
PB0658)Date and Time: All ePosters will be made
available on Saturday, July 17
uniQure Vice President of Clinical Development
David Cooper, M.D., also will give an invited presentation to the
ISTH SSC (Scientific and Standardization Committee) subcommittee
entitled “Factor VIII, Factor IX and Rare Coagulation Disorders.”
His pre-recorded presentation, Rationale for Adeno-associated Virus
(AAV) Mediated Gene Therapy in Patients with Pre-existing anti-AAV5
antibodies, will take place on Saturday, July 17 from 9:24 to 9:30
a.m.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary gene therapies to treat patients with severe genetic
diseases of the central nervous system (CNS) and liver, including
clinical programs in hemophilia B and Huntington's disease and
preclinical candidates in Fabry disease, spinocerebellar ataxia
Type 3, temporal lobe epilepsy, Alzheimer’s, Parkinson’s, and ALS.
www.uniQure.com
uniQure Contacts:
FOR INVESTORS: |
|
FOR MEDIA: |
|
|
|
Maria E. Cantor |
Chiara Russo |
Tom Malone |
Direct: 339-970-7536 |
Direct: 617-306-9137 |
Direct: 339-970-7558 |
Mobile: 617-680-9452 |
Mobile: 617-306-9137 |
Mobile:339-223-8541 |
m.cantor@uniQure.com |
c.russo@uniQure.com |
t.malone@uniQure.com |
Uniqure NV (TG:UQ1)
Historical Stock Chart
From Sep 2024 to Oct 2024
Uniqure NV (TG:UQ1)
Historical Stock Chart
From Oct 2023 to Oct 2024